News Release

News Release

News Release

View printer-friendly version << Back

Pacira Pharmaceuticals, Inc. to Close The NASDAQ Stock Market on April 8, 2013

PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 5, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, will close The NASDAQ Stock Market on Monday, April 8, 2013, in celebration of the one-year anniversary of the commercial launch of EXPAREL® (bupivacaine liposome injectable suspension). Members of the Pacira team will join Mr. Stack at the ceremony at the NASDAQ MarketSite in Times Square in New York City.

“We are honored to preside over The NASDAQ Stock Market Closing Bell to mark the one-year anniversary of the commercial launch of EXPAREL® and its successful market traction in that first year,” said Mr. Stack. “We continue to see tremendous growth in new customers and expansion in hospitals that have gained experience with the product, supporting our belief that EXPAREL provides a significant opportunity to improve patient care as well as hospital economics and provide a new treatment for postsurgical pain.”

The ceremony will be broadcast live beginning at 3:50 p.m. ET and can be accessed at:

About Pacira

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, EXPAREL® (bupivacaine liposome injectable suspension), was commercially launched in the United States in April 2012. EXPAREL and two other products have utilized the Pacira proprietary product delivery technology DepoFoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.

Additional information about Pacira is available at

Source: Pacira Pharmaceuticals, Inc.

Pacira Pharmaceuticals, Inc.
James S. Scibetta, 973-254-3570
Chief Financial Officer